![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 11, 10710-10719, March 12, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Synuclein Inclusions*











||
From the
Department of Neurology, Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyoku, Kyoto 606-8507, Japan,
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Shimoadachicho, Sakyoku, Kyoto 606-8501, Japan, and ¶Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto, Misasagi, Yamashinaku, Kyoto 607-8412, Japan
Parkinson's disease is characterized by dopaminergic neuronal death and the presence of Lewy bodies.
-Synuclein is a major component of Lewy bodies, but the process of its accumulation and its relationship to dopaminergic neuronal death has not been resolved. Although the pathogenesis has not been clarified, mitochondrial complex I is suppressed, and caspase-3 is activated in the affected midbrain. Here we report that a combination of 1-methyl-4-phenylpyridinium ion (MPP+) or rotenone and proteasome inhibition causes the appearance of
-synuclein-positive inclusion bodies. Unexpectedly, however, proteasome inhibition blocked MPP+- or rotenone-induced dopaminergic neuronal death. MPP+ elevated proteasome activity, dephosphorylated mitogen-activating protein kinase (MAPK), and activated caspase-3. Proteasome inhibition reversed the MAPK dephosphorylation and blocked caspase-3 activation; the neuroprotection was blocked by a p42 and p44 MAPK kinase inhibitor. Thus, the proteasome plays an important role in both inclusion body formation and dopaminergic neuronal death but these processes form opposite sides on the proteasome regulation in this model.
Received for publication, August 1, 2003 , and in revised form, December 10, 2003.
* This work was supported by Grant-in-aid for Scientific Research (to H. S.) from Japan Society for the Promotion of Science 14570591 and from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains Supplemental Figs. 1-4.
|| To whom correspondence should be addressed. Tel.: 81-75-751-3771; Fax: 81-75-751-3265; E-mail: i53367{at}sakura.kudpc.kyoto-u.ac.jp.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
K. Assayag, E. Yakunin, V. Loeb, D. J. Selkoe, and R. Sharon Polyunsaturated Fatty Acids Induce {alpha}-Synuclein-Related Pathogenic Changes in Neuronal Cells Am. J. Pathol., December 1, 2007; 171(6): 2000 - 2011. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Conway-Campbell, M. A. McKenna, C. C. Wiles, H. C. Atkinson, E. R. de Kloet, and S. L. Lightman Proteasome-Dependent Down-Regulation of Activated Nuclear Hippocampal Glucocorticoid Receptors Determines Dynamic Responses to Corticosterone Endocrinology, November 1, 2007; 148(11): 5470 - 5477. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yamamoto, H. Sawada, Y. Izumi, T. Kume, H. Katsuki, S. Shimohama, and A. Akaike Proteasome Inhibition Induces Glutathione Synthesis and Protects Cells from Oxidative Stress: RELEVANCE TO PARKINSON DISEASE J. Biol. Chem., February 16, 2007; 282(7): 4364 - 4372. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-h. Zhu, C. Horbinski, F. Guo, S. Watkins, Y. Uchiyama, and C. T. Chu Regulation of Autophagy by Extracellular Signal-Regulated Protein Kinases During 1-Methyl-4-Phenylpyridinium-Induced Cell Death Am. J. Pathol., January 1, 2007; 170(1): 75 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. da Costa, J. Dunys, F. Brau, S. Wilk, R. Cappai, and F. Checler 6-Hydroxydopamine but Not 1-Methyl-4-phenylpyridinium Abolishes {alpha}-Synuclein Anti-apoptotic Phenotype by Inhibiting Its Proteasomal Degradation and by Promoting Its Aggregation J. Biol. Chem., April 7, 2006; 281(14): 9824 - 9831. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Chen, J. Thorpe, and J. N. Keller {alpha}-Synuclein Alters Proteasome Function, Protein Synthesis, and Stationary Phase Viability J. Biol. Chem., August 26, 2005; 280(34): 30009 - 30017. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Snyder, K. Mensah, C. Hsu, M. Hashimoto, I. G. Surgucheva, B. Festoff, A. Surguchov, E. Masliah, A. Matouschek, and B. Wolozin {beta}-Synuclein Reduces Proteasomal Inhibition by {alpha}-Synuclein but Not {gamma}-Synuclein J. Biol. Chem., March 4, 2005; 280(9): 7562 - 7569. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Martin-Clemente, B. Alvarez-Castelao, I. Mayo, A. B. Sierra, V. Diaz, M. Milan, I. Farinas, T. Gomez-Isla, I. Ferrer, and J. G. Castano {alpha}-Synuclein Expression Levels Do Not Significantly Affect Proteasome Function and Expression in Mice and Stably Transfected PC12 Cell Lines J. Biol. Chem., December 17, 2004; 279(51): 52984 - 52990. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |